Mar 11, 2019
LO2A Licensor, Resdevco, Granted Market Approval for the Treatment of Sjögren's Syndrome in Hungary
Jan 10, 2019
Wize Pharma, Inc. Announces Publication of Peer Reviewed LOA2 Data on Treatment of Moderately Severe Sjögren's Syndrome-Related Dry Eye
Nov 20, 2018
Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis
Oct 24, 2018
Wize Pharma, Inc. Announces Closing of $4.45 Million Private Placement
Oct 23, 2018
Wize Pharma, Inc. Announces $4.45 Million Private Placement
Sep 12, 2018
Wize Pharma Appoints Ellen Lubman to its Advisory Board
Jul 26, 2018
Wize Pharma Announces Appointment of Dr. Penny Asbell, Key Opinion Leader in Dry Eye Syndrome to Advisory Board
Jun 05, 2018
Wize Pharma Signs Distribution Agreement in China for LO2A
May 22, 2018
Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
Apr 04, 2018
Wize Pharma Completes Patient Enrollment in Phase II Study of LO2A for Treatment of Patients With CCH
Mar 28, 2018
Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome
Mar 15, 2018
Wize Pharma Announces Dr. Joseph Tauber, Key Opinion Leader in Dry Eye, Joins Scientific Advisory Board
Mar 05, 2018
Wize Pharma Announces Reverse Stock Split Effective March 5, 2018
Feb 28, 2018
Wize Pharma Announces Expected Exercise of Investment Rights and Warrants for Total Proceeds of $1.14 Million
Feb 20, 2018
Wize Pharma Receives IRB Approval of Phase IV Study Protocol for LO2A in Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome